Pharmacotherapy for acute heart failure syndromes

American Journal of Health-System Pharmacy

Volumn 68, Issue 1, 2011, Pages 21-35

  Coons, James C ^a   McGraw, Molly ^a   Murali, Srinivas ^a,b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Angiotensin convertingenzyme inhibitors; Cardiac drugs; Digoxin; Diuretics; Heart failure; Hospitals; Morphine; Opiates; Protocols; Vasodilating agents; Vasopressin antagonists

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CONIVAPTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; MORPHINE SULFATE; NESIRITIDE; NITRATE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; RELAXIN; ROLOFYLLINE; TOLVAPTAN; TORASEMIDE; URODILATIN; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; MORPHINE; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART FAILURE; ANTICOAGULANT THERAPY; CARDIOGENIC SHOCK; COUNTERPULSATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; HEART RIGHT VENTRICLE FAILURE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPONATREMIA; INJECTION SITE REACTION; LUNG CONGESTION; LUNG EDEMA; MAINTENANCE THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THIRST; TREATMENT OUTCOME; XEROSTOMIA; HEART FAILURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIGOXIN; DIURETICS; DOBUTAMINE; HEART FAILURE; HUMANS; MILRINONE; MORPHINE; NATRIURETIC PEPTIDE, BRAIN; NITROGLYCERIN; NITROPRUSSIDE; PRACTICE GUIDELINES AS TOPIC; VASODILATOR AGENTS;

EID: 79953012899     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100202     Document Type: Review

References (74)

1. Jessup M, Abraham WT, Casey DE et al., on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009; 54:1343-82.
2. Curtis LH, Greiner MA, Hammill BG et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med. 2008; 168:2481-8.
3. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics 2010 update: a report from the American Heart Association. Circulation. 2010; 121:e46-215.
4. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009; 53:557-73.
5. Lindenfeld J, Albert NM, Boehmer JP et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010; 16:475-539.
6. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29:2388-442.
7. Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005; 112:3958-68. (Pubitemid 43739494)
8. Pang PS, Komajda M, Gheorghiade M. The current and future management of acute heart failure syndromes. Eur Heart J. 2010; 31:784-93.
9. Joseph SM, Cedars AM, Ewald GA et al. Acute decompensated heart failure. Tex Heart Inst J. 2009; 36:510-20.
10. Nohria A, Tsang SW, Fang JC et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003; 41:1797-804. (Pubitemid 36584255)
11. Fonarow GC, Heywood JT, Heidenreich PA et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007; 153:1021-8.
12. Ahmed A, Allman RM, Fonarow GC et al. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail. 2008; 14:211-8. (Pubitemid 351434595)
13. Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116:1482-7. (Pubitemid 47480639)
14. The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Shortterm intravenous milrinone for acute exacerbation of chronic heart failure. JAMA. 2002; 287:1541-7.
15. Fonarow GC, for the ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003; 4(suppl 7):S21-30.
16. Abraham WT, Adams KF, Fonarow GC et al. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005; 46:57-64. (Pubitemid 40905130)
17. Peacock WF, Fonarow GC, Emerman CL et al. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology. 2007; 107:44-51. (Pubitemid 46012432)
18. Levy P, Compton S, Welch R et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med. 2007; 50:144-52. (Pubitemid 47069604)
19. Maisel AS, Peacock WF, McMullin N et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure. J Am Coll Cardiol. 2008; 52:534-40.
20. Cotter G, Metzkor E, Kaluski E et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998; 351:389-93. (Pubitemid 28064161)
21. Domanski M, Norman J, Pitt B et al. Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 2003; 42:705-8. (Pubitemid 37000189)
22. Brater DC. Diuretic therapy. N Engl J Med. 1998; 339:387-95. (Pubitemid 28363803)
23. Lopez B, Querejeta R, Gonzalez A et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004; 43:2028-35. (Pubitemid 38686797)
24. Emerman CL, DeMarco T, Costanzo MR et al. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. J Card Fail. 2004; 10(suppl):S116. Abstract.
25. Constanzo MR, Heywood JT, De Marco T et al. Impact of renal insufficiency and chronic diuretic therapy on outcome and resource utilization in patients with acute decompensated heart failure. J Am Coll Cardiol. 2004; 43:180A. Abstract.
26. Cotter G, Weissgarten J, Metzkor E et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997; 62:187-93. (Pubitemid 27373467)
27. Hasselblad V, Gattis Stough W, Shah MR et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007; 9:1064-9. (Pubitemid 47451811)
28. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006; 97:1759-64. (Pubitemid 43817867)
29. Howard PA, Dunn MI. Severe heart failure in the elderly. Drugs Aging. 2002; 19:249-56.
30. Salvador DR, Rey NR, Ramos GC et al. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004; 1:CD003178.
31. Felker GM, for the NHLBI Heart Failure Clinical Research Network. Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE). Presented at the American College of Cardiology 2010/i2 Summit. Atlanta, GA; 2010 Mar.
32. Elkayam U, Janmohamed M, Habib M et al. Vasodilators in the management of acute heart failure. Crit Care Med. 2008; 36(suppl):S95-105.
33. Friederich JA, Butterworth JF. Sodium nitroprusside: twenty years and counting. Anesth Analg. 1995; 81:152-62.
34. Mullens W, Abrahams Z, Francis GS et al. Sodium nitroprusside for advanced lowoutput heart failure. J Am Coll Cardiol. 2008; 52:200-7. (Pubitemid 351915785)
35. Khot UN, Novaro GM, Popovic ZB et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003; 348:1756-63. (Pubitemid 36514706)
36. Natrecor (nesiritide) package insert. Fremont, CA: Scios, Inc.; 2009 Jun.
37. Colucci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000; 343:246-53. (Pubitemid 30490392)
38. The VMAC Investigators. Intravenous nesiritide vs. nitroglycerin for the treatment of decompensated congestive heart failure. JAMA. 2002; 287:1531-40.
39. Witteles RM, Kao D, Christopherson D et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction. J Am Coll Cardiol. 2007; 50:1835-40.
40. Cataliotti A, Boerrigter G, Costello- Boerrigter LC et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004; 109:1680-5. (Pubitemid 38451727)
41. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005; 111:1487-91. (Pubitemid 40470642)
42. Sackner-Bernstein JD, Kowalski M, Fox M et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. JAMA. 2005; 293:1900-5.
43. Hauptman PJ, Schnitzler MA, Swindle J et al. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure. JAMA. 2006; 296:1877-84. (Pubitemid 44584000)
44. Data on file. Scios, Inc., Titusville, NJ; 2007.
45. Yancy CW, Krum H, Massie BM et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure. Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail. 2008; 1:9-16.
46. Peacock WF, Holland R, Gyarmathy R et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J Emerg Med. 2005; 29:243-52. (Pubitemid 41383844)
47. ClinicalTrials.gov. Double-blind, placebocontrolled, multicenter acute study of clinical effectiveness of nesiritide in subjects with decompensated heart failure (ASCEND-HF). www.clinicaltrials.gov/ NCT00475852 (accessed 2010 Mar 29).
48. Peacock WF, Hollander JE, Diercks DB et al. Morphine and outcomes in acute decompensated heart failure: an ADHERE analysis. Emerg Med J. 2008; 25:205-9. (Pubitemid 351493056)
49. Swedberg K, Held P, Kjekshus J et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992; 327:678-84.
50. Silvers SM, Howell JM, Kosowsky JM et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med. 2007; 49:627-69. (Pubitemid 46601692)
51. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006; 113:2556-64. (Pubitemid 43948035)
52. Gheorghiade M, Braunwald E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA. 2009; 302:2146-7.
53. Bayram M, De Luca L, Massie MB et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005; 96(suppl):47G-58G.
54. Marino PL. The ICU book, 2nd ed. Baltimore: Williams & Wilkins; 1998.
55. Aranda JM, Schofield RS, Pauly DF et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J. 2003; 145:324-9.
56. Burger AJ, Horton DP, LeJemtel T et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002; 144:1102-8. (Pubitemid 36026926)
57. Baruch L, Patacsil P, Hameed A et al. Pharmacodynamic effects of milrinone with and without a bolus loading infusion. Am Heart J. 2000; 141:e6.
58. Yamani MH, Showkat A, Starling RC et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy, clinical outcome, and economic impact. Am Heart J. 2001; 142:998-1002. (Pubitemid 33131808)
59. Bristow MR, Shakar SF, Linseman JV et al. Inotropes and β-blockers: is there a need for new guidelines? J Card Fail. 2001; 7(suppl 1):8-12. (Pubitemid 33732173)
60. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005; 46:1785-91. (Pubitemid 41579797)
61. Klein L, O'Connor CM, Leimberger JD et al., for the OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005; 111:2454-60. (Pubitemid 40696133)
62. Vaprisol (conivaptan hydrochloride for injection) package insert. Deerfield, IL: Astellas Pharm US; 2008 Oct.
63. Samsca (tolvaptan) package insert. Tokyo, Japan: Otsuka Pharmaceutical Co.; 2009 May.
64. The EVEREST Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA. 2007; 297:1319-31.
65. Pfisterer M, Buser P, Rickli H et al., for the TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy. JAMA. 2009; 301:383-92.
66. Lainchbury JG, Troughton RW, Strangman KM et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure. J Am Coll Cardiol. 2010; 55:53-60.
67. Pina IL, O'Connor C. BNP-guided therapy for heart failure. JAMA. 2009; 301:432-4.
68. Gattis WA, O'Connor CM, Gallup DS et al., on behalf of the IMPACT-HF Investigators. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. J Am Coll Cardiol. 2004; 43:1534-41.
69. Butler J, Young JB, Abraham WT et al., for the ESCAPE Investigators. Beta-blocker use and outcomes among hospitalized heart failure patients. J Am Coll Cardiol. 2006; 47:2462-9. (Pubitemid 43866386)
70. Fonarow GC, Abrahm WT, Albert NM et al., on behalf of the OPTIMIZE-HF Investigators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure. J Am Coll Cardiol. 2008; 52:190-9. (Pubitemid 351927267)
71. Jondeau G, Neuder Y, Eicher J et al., for the B-CONVINCED Investigators. B-CONVINCED: beta-blocker continuation vs. interruption in patients with congestive heart failure hospitalized for a decompensation episode. Eur Heart J. 2009; 30:1-7.
72. DeGoma EM, Vagelos RH, Fowler MB et al. Emerging therapies for the management of decompensated heart failure. J Am Coll Cardiol. 2006; 48:2397-409. (Pubitemid 44881226)
73. Cleland JG, Coletta AP, Yassin A et al. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT. Eur J Heart Fail. 2009; 11:1214-9.
74. Mebazaa A, Nieminen MS, Packer M et al., for the SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure. JAMA. 2007; 297:1883-91. (Pubitemid 46707842)